CASE REPORT

Clinical Regression of Chondrosarcoma Applying High Doses of Viscum album extracts (VAE) by Intratumoral Injection: A Case Report

Joon Beom (John) Park.1 Inmyung Oh.2 Sunjoo Chung.2 Taek Joon Yoon.3 JongBae Kim.1 

• .1Mistletoe Research Center, New Breath Hospital, Seoul 
• .2Mistletoe Cancer Clinic, New Breath Hospital, Seoul 
• .3DoGenBio, Independent Researcher & Consultant, Seoul
•  

Corresponding Author: Joon Beom (John) Park, Mistletoe Research Center, New Breath Hospital, KD70 Jeungui-ro 8-gil 4, Songpa-gu, Seoul, Korea. E-mail: [email protected]

Received: April 12, 2024                                                       Published: April 30, 2024

Citation: Joon Beom Park. Clinical Regression of Chondrosarcoma Applying High Doses of Viscum album extracts (VAE) by Intratumoral Injection: A Case Report. Int J Complement Intern Med. 2024;6(1):246–253. DOI: 10. 58349/IJCIM. 1. 6. 2024. 00138

Copyright: ©2024 Park. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Abstract 

Mistletoe lectins (ML/VAL) are known to induce apoptotic cell death. Intratumoral applications of Viscum album extract (VAE) have induced local tumor response in various cancer entities for variant carcinomas. A 46-year-old male patient suffering from chondrosarcoma had two large-sized masses (40 cm x 25 cm x 17 cm) and a satellite tumor (8 cm x 14 cm x 3 cm). The patient was treated with by 24 times Abnobaviscum F (fraxini) 20 mg intratumoral injections and concomitant administration of 19 times Helixor A (abietis) 100 mg IV infusions weekly. 32 weeks after treatment the tumoral parenchyma showed a significant regression (>70% of the tumor size) These treatments aimed to improve survival and QoL by reducing tumor burden and symptoms, such as shortness of breath, coughing, hemoptysis, and cachexia. Retrospectively, on average, the lectin amount in one ampoule of Abnobaviscum F 20 mg was 205.2 ng/ml. As eight ampoules of Abnobaviscum F 20 mg (total 160 mg) were injected into the patient a day by intratumoral application, up to 1,642 ng/ml of mistletoe lectin (ML) was injected as the extending maximum high-dose in safety. The concentration of VAL was determined by ELISA. Reference mistletoe lectin was isolated using an immunoaffinity column with lectinspecific monoclonal antibodies. 

Keywords: mistletoe, chondrosarcoma, intratumoral mistletoe injection, Viscum album, lectin

References 

1. Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999 Jan-Feb;19(1A):23-28. 

2. Carrie Y Inwards, Jodi M. Carter and André M. Oliveira Diagnostic Histopathology of Tumors, Chapter 25, 2002-2066. 

3. Dierselhuis EF, Gerbers JG, Ploegmakers JJW, et al. Local treatment with adjuvant therapy for central atypical cartilaginous tumors in the long bones. Journal of Bone and Joint Surgery. 2016;98(4):303-313. 

4. Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. The Oncologist. 2008;13(3):320-329. 

5. Hajtó T, Hostanska K, Berki T, et al. Oncopharmacological perspectives of a plant lectin (viscum albumagglutinin-I): Overview of recent results fromin vitroexperiments andin vivoanimal models, and their possible relevance for clinical applications. Evidence Based Complementary and Alternative Medicine. 2005;2(1):59-67. 

6. Majeed M, Hakeem KR, Rehman RU. Mistletoe lectins: From interconnecting proteins to potential tumour inhibiting agents. Phytomedicine Plus. 2021;1(3):100039. 

7. Mavrogenis AF, Angelini A, Drago G et al. Survival analysis of patients with chondrosarcomas of the pelvis. Journal of Surgical Oncology. 2013;108(1):19-27. 

8. Meftah M, Schult P, Henshaw RM. Long-term results of intralesional curettage and cryosurgery for treatment of lowgrade chondrosarcoma. The Journal of Bone and Joint SurgeryAmerican Volume. 2013;95(15):1358-1364. 

9. Orange M, Fonseca M, Lace A et al. Durable tumour responses following primary high dose induction with mistletoe extracts: two case reports. Eur J Integr Med. 2010;2:63-69. 

10. Schwab JH, Wenger D, Unni K et al. Does local recurrence impact survival in low-grade chondrosarcoma of the long bones? Clin Orthop Relat Res. 2007;462:175-80. 

11. Werthmann PG, Helling D, Heusser P et al. Tumour response following high-dose intratumoural application of Viscum album on a patient with adenoid cystic carcinoma. BMJ Case Rep. 2014;31:2014:bcr2013203180. 

12. Werthmann PG, Huber R, Kienle GS. Durable Clinical Remission of a Skull Metastasis under Intralesional Viscum album Extract Therapy: Case Report. Head & Neck. 2018;40(7):E79. 

13. Werthmann PG, Sträter G, Friesland H, et al. Durable response of cutaneous squamous cell carcinoma following high dose peri-lesional injections of Viscum album extracts -- a case report. Phytomedicine. 2013;20:324-327.